Reflux Laryngitis Medication
- Author: Bardia Amirlak, MD; Chief Editor: Arlen D Meyers, MD, MBA more...
A variety of pharmacologic agents are available for suppressing gastric acid secretion. These include H2RAs such as famotidine, ranitidine, nizatidine, and cimetidine; proton pump inhibitors (PPIs) such as omeprazole; prokinetic agents such as cisapride and tegaserod; and mucosal cytoprotectants such as sucralfate. Evidence that supports the efficacy of the H2RAs is questionable. PPIs are significantly more potent and reliably achieve a greater magnitude of gastric acid inhibition. In addition, compared with esophageal symptoms, significantly greater acid inhibition is required to relieve supraesophageal symptoms and, especially, to achieve mucosal healing. Hence, the choice of PPIs over H2RAs is clear as a first-line pharmacologic intervention.
Omeprazole has been studied most extensively and is the only agent used in the clinical trials evaluating efficacy of PPIs in supraesophageal disorders. However, experience with lansoprazole is increasing, and newer agents (rabeprazole, pantoprazole) promising sustained and more potent gastric acid suppression with once daily dosing have recently arrived.
Prokinetic agents accelerate esophageal clearance and increase lower esophageal sphincter (LES) tone. The prokinetic agent cisapride has been discontinued because of serious adverse effects or ventricular arrhythmia. Tegaserod decreases reflux and LES relaxation events and is useful for treating laryngopharyngeal reflux (LPR) associated with esophageal dyskinesia.
Tegaserod was temporarily withdrawn from the US market in March 2007; however, as of July 27, 2007, restricted use of tegaserod is now permitted via a treatment IND protocol. The treatment IND will allow tegaserod treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in women younger than 55 years who meet specific guidelines. Its use is further restricted to those in critical need who have no known or preexisting heart disease.
Earlier this year, tegaserod marketing was suspended because of a meta-analysis of safety data pooled from 29 clinical trials that involved more than 18,000 patients. The results showed an excess number of serious cardiovascular adverse events, including angina, myocardial infarction, and stroke, in those taking tegaserod compared with placebo. In each study, patients were assigned at random to either tegaserod or placebo. Tegaserod was taken by 11,614 patients, and placebo was taken by 7,031 patients. The average age of patients in these studies was 43 years, and most patients (ie, 88%) were women. Serious and life-threatening cardiovascular adverse effects occurred in 13 patients (0.1%) treated with tegaserod; among these, 4 patients had a heart attack (1 died), 6 had unstable angina, and 3 had a stroke. Among the patients taking placebo, only 1 (0.01%) had symptoms suggesting the beginning of a stroke that went away without complication. For more information, see the FDA MedWatch Product Safety Alert.
Sucralfate is a polysulfated salt of sucrose that may be helpful as an adjunct in protecting injured mucosa from the harmful effects of acid and pepsin.
Proton pump inhibitors
Inhibit gastric acid secretion by inhibition of the H+/K+ -ATPase enzyme system in the gastric parietal cells.
Specifically suppress gastric acid secretion by potent inhibition of the H+/K+ -ATPase enzyme system at secretory surface of gastric parietal cell. This blocks the final step in gastric acid production. Effect is dose related and inhibits both basal and meal-stimulated acid secretion. Omeprazole has been studied most extensively and is the only agent used in the clinical trials evaluating efficacy in supraesophageal disorders.
Suppresses gastric acid secretion by specific inhibition of the H+/K+ -ATPase enzyme system (ie, proton pump) at the secretory surface of the gastric parietal cell. It blocks the final step of acid production. The effect is dose related and inhibits both basal and stimulated gastric acid secretion, thus increasing gastric pH levels.
Suppresses gastric acid secretion by specifically inhibiting H+/K+ -ATPase enzyme system at the secretory surface of gastric parietal cells. Use of the IV preparation has only been studied for short-term use (ie, 7-10 d).
These agents may stimulate peristaltic reflex.
Tegaserod hydrogen maleate (Zelnorm)
Available in US by restricted treatment IND for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in women younger than 55 years who meet specific guidelines. Used for the short-term treatment of women with irritable bowel syndrome in whom constipation is the predominant symptom. Serotonin type 4 receptor partial agonist with no affinity for 5-HT3 receptors. May trigger peristaltic reflex via 5-HT4 activation, which enhances basal motor activity and normalizes impaired GI motility. Research studies have shown inhibitory activity of the drug on visceral activity in the GI tract.
These agents may protect the GI lining against peptic acids.
Binds to positively charged proteins in exudates and forms a viscous, adhesive substance that protects GI lining against pepsin, peptic acid, and bile salts. Used for short-term ulcer management.
Cherry J, Margulies SI. Contact ulcer of the larynx. Laryngoscope. 1968 Nov. 78(11):1937-40. [Medline].
Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991 Apr. 101(4 Pt 2 Suppl 53):1-78. [Medline].
Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005 Sep 28. 294(12):1534-40. [Medline].
Vaezi MF. Benefit of acid-suppressive therapy in chronic laryngitis: the devil is in the details. Clin Gastroenterol Hepatol. 2010 Sep. 8(9):741-2. [Medline].
Maronian NC, Azadeh H, Waugh P, Hillel A. Association of laryngopharyngeal reflux disease and subglottic stenosis. Ann Otol Rhinol Laryngol. 2001 Jul. 110(7 Pt 1):606-12. [Medline].
Reavis KM, Morris CD, Gopal DV, Hunter JG, Jobe BA. Laryngopharyngeal reflux symptoms better predict the presence of esophageal adenocarcinoma than typical gastroesophageal reflux symptoms. Ann Surg. 2004 Jun. 239(6):849-56; discussion 856-8. [Medline].
Burton LK Jr, Murray JA, Thompson DM. Ear, nose, and throat manifestations of gastroesophageal reflux disease. Complaints can be telltale signs. Postgrad Med. 2005 Feb. 117(2):39-45. [Medline].
Milstein CF, Charbel S, Hicks DM, Abelson TI, Richter JE, Vaezi MF. Prevalence of laryngeal irritation signs associated with reflux in asymptomatic volunteers: impact of endoscopic technique (rigid vs. flexible laryngoscope). Laryngoscope. 2005 Dec. 115(12):2256-61. [Medline].
Gill GA, Johnston N, Buda A, Pignatelli M, Pearson J, Dettmar PW. Laryngeal epithelial defenses against laryngopharyngeal reflux: investigations of E-cadherin, carbonic anhydrase isoenzyme III, and pepsin. Ann Otol Rhinol Laryngol. 2005 Dec. 114(12):913-21. [Medline].
Eckley CA, Sardinha LR, Rizzo LV. Salivary concentration of epidermal growth factor in adults with reflux laryngitis before and after treatment. Ann Otol Rhinol Laryngol. 2013 Jul. 122 (7):440-4. [Medline].
Andersson O, Moller RY, Finizia C, Ruth M. A more than 10-year prospective, follow-up study of esophageal and pharyngeal acid exposure, symptoms and laryngeal findings in healthy, asymptomatic volunteers. Scand J Gastroenterol. 2009. 44(1):23-31. [Medline].
Altman KW, Stephens RM, Lyttle CS, Weiss KB. Changing impact of gastroesophageal reflux in medical and otolaryngology practice. Laryngoscope. 2005 Jul. 115(7):1145-53. [Medline].
Martins RH, do Amaral HA, Tavares EL, Martins MG, Goncalves TM, Dias NH. Voice Disorders: Etiology and Diagnosis. J Voice. 2015 Nov 4. [Medline].
Ahmed TF, Khandwala F, Abelson TI, et al. Chronic laryngitis associated with gastroesophageal reflux: prospective assessment of differences in practice patterns between gastroenterologists and ENT physicians. Am J Gastroenterol. 2006 Mar. 101(3):470-8. [Medline].
Belafsky PC, Postma GN, Koufman JA. The association between laryngeal pseudosulcus and laryngopharyngeal reflux. Otolaryngol Head Neck Surg. 2002 Jun. 126(6):649-52. [Medline].
Malhotra A, Freston JW, Aziz K. Use of pH-impedance testing to evaluate patients with suspected extraesophageal manifestations of gastroesophageal reflux disease. J Clin Gastroenterol. 2008 Mar. 42(3):271-8. [Medline].
So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery. 1998 Jul. 124(1):28-32. [Medline].
Salminen P, Karvonen J, Ovaska J. Long-term outcomes after laparoscopic Nissen fundoplication for reflux laryngitis. Dig Surg. 2010. 27(6):509-14. [Medline].
Grossman TW, Toohill RJ, Mushtag E, et al. Pharyngeal, laryngeal and tracheobronchial manifestations of gastroesophageal reflux. Proceedings of the XXIV World Congress of Otolaryngology Head and Neck Surgery. Berkley, Calif: Kugler and Ghedini Publishing;
- Table 2. shows key features of the 7 studies that evaluated efficacy of antireflux medical treatment. These studies were published from 1991-1997 and reported on 346 adult patients with otherwise unexplained posterior laryngitis suspected to be caused by GERD who received antireflux medical treatment in an uncontrolled nonblinded clinical trial. Outcomes Reported by Trials of Antireflux Medical Treatment of Reflux Laryngitis
|Author||n||Pharmacologic Intervention||Treatment Duration
|Symptom Improvement||Laryngoscopic Improvement||Follow-up
|Koufman||33||Ranitidine 300-600 mg/d or
Famotidine 80 mg/d
|Kamel||16||Omeprazole 40 mg/d||6-24||79%||96%||56%||6||Majority|
Famotidine 20 mg/d,
Omeprazole 20-40 mg/d
|Shaw||68||Omeprazole 20 mg bid||12||Significantly improved||40%||Significantly improved||None||…|
|Wo||21||Omeprazole 40 mg/d||8||40%||48%||50%||8||38%|
|Metz||10||Omeprazole 20 mg bid||4||60%||100%||…||…||…|
|Hanson||16||Omeprazole 20 mg/d||6-9||Significantly improved acoustic parameters||…||…||…||…|